Business · Companies · 8 hrs ago
Sanofi considers buying US drugmaker Insmed
Sanofi is considering buying US drugmaker Insmed, but no deal has been agreed.
Bloomberg says Sanofi has hired advisers and talks could continue for weeks.
Insmed shares rose by as much as 24% on Thursday, valuing the company at about $30 billion, while Sanofi shares fell nearly 4%.
An offer could cost more than Insmed's current market value and be near the upper limit of what Sanofi can afford, according to an analyst.
Sanofi is seeking new medicines to offset potential revenue losses when the patent on Dupixent, its top-selling treatment for skin conditions and asthma, expires.
Sanofi sees acquisitions as a way to grow, but other buyers could make offers and the outcome remains uncertain.
Sanofi is considering buying US drugmaker Insmed and has engaged advisers, according to a Bloomberg report cited by Handelsblatt.
Talks are ongoing, but an agreement could still be weeks away and a deal is not certain.
Insmed was valued at about $30 billion after its shares rose by as much as 24 percent on Thursday.
Sanofi is seeking acquisitions to secure new medicines and offset potential revenue losses when the patent on its top-selling drug Dupixent expires.
- Who
- French drugmaker Sanofi is considering buying US drugmaker Insmed.
- What
- Sanofi is examining an acquisition and has engaged advisers, according to the report.
- When
- Handelsblatt reported on November 19, 2026; talks are ongoing.
- Where
- Sanofi is based in Paris, and Insmed is a US drugmaker.
- Why
- Sanofi is seeking new medicines to offset revenue losses when the patent on Dupixent expires.
This story does not have two clearly opposing sides.
Belén Garijo took over as Sanofi chief executive from Paul Hudson.
Garijo said Sanofi would use acquisitions as a growth driver.
Handelsblatt reported that Sanofi was examining a possible Insmed purchase and had engaged advisers.
Insmed shares rose by as much as 24 percent, while Sanofi shares fell nearly 4 percent in Paris.
- Insmed market value
- About $30 billion
- Insmed share rise
- As much as 24 percent on Thursday
- Sanofi share move
- Down nearly 4 percent in Paris
- Potential deal timing
- An agreement could be weeks away
- Sanofi drug
- Dupixent, its top-selling medicine for skin diseases and asthma
What people are saying
The purchase price will probably be above the current market capitalization and would therefore be at the upper end of Sanofi’s financial capacity but by no means unattainable.